This is a demo store. No orders will be fulfilled.
In Vitro Diagnostics (IVD)
-
21 Jun 2019  |  Asia Pacific  |  Market Research
Chinese In-vitro Diagnostics Market Insight, Forecast to 2023
The China Manufacturing 2025 Program for Promoting Local R&D Investments and Increasing Demand from Tier I and II Hospitals Set to Transform the Industry Landscape
The In-vitro Diagnostics (IVD) market in China shows strong growth potential in several segments. Market growth is set to be driven by the growing volume of tests, rather than the higher price of testing solutions in traditional segments and the popularization of advanced testing technology in emerging segments. In the context of the reform in publ...
$1,500.00 -
08 Jun 2018  |  North America  |  Market Research
US Cardiac Troponin Diagnostics Market, Forecast to 2021
High Prevalence of Heart Disease Propels Market Growth
Cardiac troponins help to diagnose nearly two-thirds of the patients in the diagnosis Acute Coronary Syndrome (ACS) who are missed out by Echocardiogram (ECG). ECG can detect only one-third of the patients with persistent ST-segment Elevation (STEMI), whereas cardiac troponins can distinguish patients without ST-segment elevation (NSTEACS; non-ST s...
$4,950.00 -
25 May 2018  |  Europe  |  Market Research
Western European Cardiac Troponin Diagnostics Market, Forecast to 2021
Emerging Biomarkers Disrupt and Spur Growth in the Heart Disease Segment
Cardiac troponins have now become the gold standard for early diagnosis of acute myocardial infarction, making them indispensable for clinical diagnosis of Acute Coronary Syndrome (ACS). Cardiac troponins play a key role in minimizing hospital stays and reducing admission rate which are the biggest contributors to overall healthcare expenditure. Fo...
$3,000.00 -
16 Apr 2018  |  Asia Pacific  |  Market Research
Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021
Increasing Incidence Rates of Myocardial Infarction and Aging Population in APAC Drive the Troponin Diagnostics Market
Cardiac troponins will continue to remain the gold standard for early diagnosis of acute myocardial infarction (AMI); however, the key challenge to address is the advent of a complementary biomarker to prevent repeat diagnosis. Multiplexing platforms should be harnessed for simultaneous testing of complementary biomarkers such as H-FABP, cardiac my...
$3,000.00